Investment
Features
FeesSafety
Academy
More
Pluang+

Compare REX AI Equity Premium Income ETF (AIPI) vs Cardinal Health Inc (CAH) Price & Performance

REX AI Equity Premium Income ETFTrade
Cardinal Health IncTrade

Price performance (Past 24H)

Key statistics

REX AI Equity Premium Income ETF vs Cardinal Health Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.35, while Cardinal Health Inc trades at $236.72 (market cap $55.88B). The key difference: Cardinal Health Inc pays a 0.86% dividend while REX AI Equity Premium Income ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

AIPICAH
Sector
Income / Options OverlayHealth
52-Week High
$44.93$240.26
52-Week Low
$32.45$146.04
Market Cap
$55.88B
Enterprise Value
$59.91B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

REX AI Equity Premium Income ETF

AIPI (REX AI Equity Premium Income ETF) trades at $37.41 with minimal daily movement (+0.19%). The ETF employs an option-writing strategy focused on AI-related equities, generating substantial weekly dividends averaging $0.24-0.26 per distribution. Technical indicators show mixed signals with bullish moving averages but overbought RSI levels. The fund's unique structure provides high income but faces sustainability concerns if AI market momentum falters.

AIPI offers exceptional yield potential through its weekly distribution model but carries structural risks including potential NAV erosion. The ETF's performance depends heavily on continued AI sector strength and effective options management. Investors should weigh the high income against the fund's capped upside and concentration in technology stocks during market volatility.

Cardinal Health Inc

Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.

Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About REX AI Equity Premium Income ETF

AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.

Read more on AIPI

About Cardinal Health Inc

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Read more on CAH